Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Bone and Calcium Disorders
Is the FRAX score reliable in assessing fracture risk for patients with history of prior bisphosphonate use?
Related Questions
What is your approach to IV fluid management for the treatment of hypercalcemia of malignancy?
In a patient with a history of parathyroidectomy (due to primary hyperparathyroidism) with low T- scores and high risk of fractures, is there any contraindication to give teriparatide/Forteo if PTH is in normal range after surgery?
Would you start romosozumab in an active smoker?
Is there a target alkaline phosphatase level for hypophosphatasia patients on asfotase alfa therapy?
How do you approach vitamin D supplementation in patients with chronic kidney disease, given the findings that vitamin D2 supplementation may lead to decreased conversion of 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3?
Is there a maximum duration for raloxifene use?
Would you consider the use of romosozumab in men who have failed therapy with teriparatide and sustained multiple vertebral fractures?
In a patient with severe osteoporosis (T-score -3.9) and multiple vertebral fractures in the setting of multiple myeloma with bone involvement, would you consider adding an anabolic agent such as romosozumab or teriparatide despite concerns about osteosarcoma risk?
Is it reasonable to tell patients that Evenity lowers fracture risk by about 70%, while Prolia reduces it by around 50%?
What is the optimal management of pain and loss of function due to pathologic compression fractures?
